Trading IdeasFundamentals

FDC Limited

NSE: FDC · Pharmaceuticals · sector

₹346.45NSE close 2026-10-26

Key numbers

Market cap₹5,640 cr
Price₹346.45
52w high / low₹474 / ₹313
P/E19.3xSector median 27.9x
P/B2.3xSector median 2.9x
Book value₹152.7
Dividend yield1.43%Sector median 0.48%
ROE12.3%Sector median 11.7%
ROCE15.9%Sector median 12.3%
OPM14.4%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA16.3xSector median 18.6x
Interest cover84.8x
Current ratio3.11x
Sales growth 3y+6.8%Sector median +9.6%
Profit growth 3y+13.2%Sector median +13.3%
PEG1.37x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹564.90 · low ₹328.05
Sep 2024Apr 2025Oct 2025Apr 2026

Quarterly results

₹ crSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue514464492648473465585668
EBITDA7047541403431106143
OPM %13.7%10.1%11.0%21.6%7.1%6.8%18.2%21.4%
Other income3519163621215048
Net profit7337391212828103132
EPS (₹)4.432.282.387.451.751.746.358.14
Revenue YoY-7.9%+0.1%+18.9%+3.0%
Profit YoY-61.3%-24.5%+167.4%+9.2%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ crFY22FY23FY24FY25FY26TTM
Revenue1,5281,7841,9432,1082,1712,190
EBITDA254251339325325315
Net profit7194305267281293
EPS (₹)12.8111.6618.5816.3917.2917.98
Revenue growth+16.7%+8.9%+8.5%+3.0%+3.4%
Profit growth+2,668.0%+57.3%-12.6%+5.5%+8.0%
Dividend / share (₹)–––5.005.00
Compounded growth3 years5 yearsLast 12 months
Sales+6.8%+10.2%+3.4%
Net profit+13.2%-1.4%+8.0%
EPS+14.0%-0.5%–
Share price–-20.5% (2y)-24.3%

Balance sheet

₹ crFY22FY23FY24FY25FY26
Shareholders' equity–1,9822,0972,2812,485
Borrowings–1000
Cash & equivalents–482476537523
Total assets–2,3432,4682,7142,919
Fixed assets–695677848952
Capital work in progress–19826113696
Investments–348393543575
Receivables–123117109152
Inventory–329389375355
Payables–178186205207

Year-end figures from the March annual filing.

Cash flow

₹ crFY22FY23FY24FY25FY26
Cash from operations162155221318200
Cash from investing-14511-17-200-110
Cash from financing-10-180-202-92-93
Capex1331139397187
Free cash flow294212722114

Free cash flow = cash from operations − capex.

Ratios by year

₹ crFY22FY23FY24FY25FY26
ROE %–9.8%14.6%11.7%11.3%
ROCE %–13.2%19.1%15.9%15.3%
Debtor days–25221926
Inventory days–183216186182
Payable days–99103102106
Cash conversion cycle (days)–109135103102
Working capital days–155151125129

Shareholding

Holder% (2026-09-30)
Promoters69.66%
FIIs1.58%
DIIs6.59%
of which Mutual funds6.48%
of which Insurance0.06%
Public (non-institutions)22.17%
QuarterDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters %69.66%69.66%69.66%69.66%69.66%69.66%69.66%69.66%
Promoter group%
Nomita R Chandavarkar22.67%
NANDAN MOHAN CHANDAVARKAR (In the capacity of Trustee of Sandhya Mohan Chandavarkar Trust)12.45%
NANDAN MOHAN CHANDAVARKAR (In the capacity of Trustee of Mohan Anand Chandavarkar Trust)12.45%
Leo Advisors Private Limited (In capacity of Trsutee of Ameya Family Discretionary Trust)9.17%
Aditi C Bhanot6.80%
Ameya Ashok Chandavarkar6.10%
Nandan Mohan Chandavarkar0.01%
Meera Ramdas Chandavarkar0.00%
Mohan Chandavarkar0.00%
Sandhya Chandavarkar0.00%
Alpana Nandan Chandavarkar0.00%
Anandi Nandan Chandavarkar0.00%
Shivani Nandan Chandavarkar0.00%
Vasant Anand Chandavarkar0.00%
Capt. Girish Anand Kaushik0.00%
Public holders above 1%%
ICICI Prudential Smallcap Fund2.91%
Nippon Life India Trustee Ltd-a/c Nippon India Small CAP Fund2.63%

54,621 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

CompanyMarket capP/EP/BROEROCEOPMSales 3yDiv yield
SUNPHARMA₹4,17,478 cr34.5x5.0x15.5%18.7%28.6%+10.0%0.94%
DIVISLAB₹2,39,825 cr82.1x14.3x18.4%23.0%34.7%+10.8%0.34%
TORNTPHARM₹1,53,999 cr72.7x18.4x27.3%15.1%32.3%+13.3%0.84%
ZYDUSLIFE₹1,15,808 cr25.9x4.3x17.7%16.8%27.2%+16.4%0.95%
LAURUSLABS₹1,11,232 cr101.6x21.0x22.4%20.8%28.0%+4.1%0.08%
CIPLA₹1,09,464 cr32.5x3.2x10.3%13.2%17.7%+7.4%1.18%
DRREDDY₹1,09,460 cr33.9x2.9x9.0%10.1%15.5%+11.0%0.61%
MANKIND₹95,486 cr46.7x5.9x13.4%13.8%25.1%+17.7%0.04%
AUROPHARMA₹91,489 cr24.9x2.4x10.5%12.8%20.0%+10.6%0.26%
FDC₹5,640 cr19.3x2.3x12.3%15.9%14.4%+6.8%1.43%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-dateActionDetail
2026-02-11DividendInterim Dividend - Rs 5 Per Share
2024-11-22DividendInterim Dividend - Rs 5 Per Share
2024-09-19OtherAnnual General Meeting
2023-09-20OtherAnnual General Meeting
2023-08-25BuybackBuy Back
2022-09-13OtherAnnual General Meeting
2022-02-17BuybackBuy Back
2021-09-20OtherAnnual General Meeting
2020-09-22OtherAnnual General Meeting
2020-08-20BuybackBuyback
2020-03-19DividendInterim Dividend - Rs 0.80 Per Share
2019-09-19OtherAnnual General Meeting
2019-06-06BuybackBuyback
2018-08-30OtherAnnual General Meeting
2018-02-26BuybackBuyback
2017-08-08DividendAnnual General Meeting/Dividend - Rs 2.25 Per Share
2016-09-06OtherAnnual General Meeting
2016-03-17DividendInterim Dividend - Rs 2.25/- Per Share
2015-09-23DividendAnnual General Meeting/ Dividend - Rs 2.25/- Per Share
2014-07-28DividendAnnual General Meeting/Dividend Rs 2.25/- Per Share

Documents

Links go to the original files on the exchange website.

About the company

SectorHealthcare
IndustryPharmaceuticals
Sub-industryPharmaceuticals
SymbolFDC
BSE code531599
ISININE258B01022
Face value₹1.0
Incorporated1940-09-23
Websitehttps://www.fdcindia.com
Plants (India / abroad)9 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.